Feed NAMS
NA

NewAmsterdam Pharma Company N.V.

NAMS · NASDAQ

$27.96 -0.32% (-$0.09)
1M -22.97%
Market Cap $3.2B
P/E Ratio -
Div. Yield -
ROE 28.55%
Valuation
21 /100
Expensive
P/B 4.73x
P/S 143.75x
P/FFO N/A
Growth
22 /100
Declining
Book val. growth 16.70%
Rev. growth 39.71%
FCF growth N/A
Profitability
20 /100
Weak
Op. margin 1,002.90%
Gross margin 99.74%
FCF margin 657.82%
Quality
0 /100
Poor
ROA 26.49%
ROIC 33.01%
Asset turnover 0.03x
Debt
100 /100
Low
Current ratio 7.88x
Debt/Equity 0.00x
Debt/Assets N/A
Stability
10 /100
Unstable
EPS volatility 56.24%
Beta 0.08x
Profitable years 0
Întreabă StockBot despre NAMS
Online

Sector

Healthcare

Industry

Biotechnology

CEO

Michael Davidson

Employees

100

Headquarters

Naarden

Evenimente viitoare

04 NOV.

Earnings

Upcoming earnings report

88d

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.